Aspirin use and the risk of cholangiocarcinoma-Reference-Cited by-同舟云学术

Aspirin use and the risk of cholangiocarcinoma

Published:2016-04-26 Issue:3 Volume:64 Page:785-796
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Choi Jonggi¹,Ghoz Hassan M.¹,Peeraphatdit Thoetchai¹²,Baichoo Esha¹³,Addissie Benyam D.¹,Harmsen William S.⁴,Therneau Terry M.⁴,Olson Janet E.⁵,Chaiteerakij Roongruedee¹⁶,Roberts Lewis R.¹

Affiliation:

1. Division of Gastroenterology and Hepatology; Mayo Clinic College of Medicine; Rochester MN, USA

2. Department of Internal Medicine; University of Minnesota; Minneapolis MN, USA

3. Department of Medicine; Mount Sinai Roosevelt Hospital; New York NY

4. Department of Biomedical Statistics and Informatics; Mayo Clinic College of Medicine; Rochester MN, USA

5. Division of Epidemiology, Department of Health Sciences Research; Mayo Clinic; Rochester MN, USA

6. Department of Medicine, Faculty of Medicine; Chulalongkorn University and King Chulalongkorn Memorial Hospital; Thai Red Cross Society Bangkok Thailand

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hep.28529/fullpdf

Reference32 articles.

1. Geographic variation of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and hepatocellular carcinoma in the United States;Altekruse;PloS One,2015

2. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma;Bridgewater;J Hepatol,2014

3. Hilar cholangiocarcinoma;Zaydfudim;Surg Oncol Clin N Am,2014

4. Risk factors for cholangiocarcinoma;Tyson;Hepatology,2011

5. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study;Shaib;Gastroenterology,2005

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial;The Lancet Gastroenterology & Hepatology;2024-08

2. Transposon-based oncogene integration in Abcb4(Mdr2)-/- mice recapitulates high susceptibility to cholangiocarcinoma in primary sclerosing cholangitis;Journal of Hepatology;2024-07

3. Cholangiocarcinoma of the Common Bile Duct Presenting as Empyema of the Gallbladder: A Rare Case Report;Cureus;2024-05-08

4. Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma;Cancers;2024-04-26

5. A Case of Cholecystitis Camouflaging Cholangiocarcinoma;Cureus;2024-03-03